Dr Laurie Harris, DO in Crandall, TX - General Practice

Dr Laurie Harris, DO is a General Practice physician based in Crandall, Texas. Dr Laurie Harris is licensed to practice in Texas (license number G9115) and her current practice location is 1017 W.hwy 175, Crandall, Texas. She can be reached at her office (for appointments etc.) via phone at (972) 427-3951.

NPI number for Dr Laurie Harris is 1700093606 and her current mailing address is Po Box 887, Crandall, Texas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1700093606.

Contact Information

	Dr Laurie Harris, DO
	1017 W.hwy 175, Crandall, TX 75114
	(972) 427-3951
	(972) 427-3684

Physician's Profile

Full Name	Dr Laurie Harris
Gender	Female
Speciality	General Practice
Location	1017 W.hwy 175, Crandall, Texas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1700093606
Provider Enumeration Date: 05/17/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Laurie Harris such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1700093606	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	G9115 (Texas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Laurie Harris is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Laurie Harris, DO Po Box 887, Crandall, TX 75114-0887 Ph: (972) 427-3951	Dr Laurie Harris, DO 1017 W.hwy 175, Crandall, TX 75114 Ph: (972) 427-3951

News Archive

Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Transcatheter heart valve technologies are positioned to become the next disruptive influence in cardiovascular medicine and drive a multi-billion dollar market. However, questions remain about the timing of adoption of these new technologies, the numbers and types of patients ultimately benefitting from them, the impact of reimbursement, and where transcatheter technologies pose the greatest threat to the current surgical caseload, especially in light of developments in minimally invasive heart valve surgery technologies.

Breast cancer drug bevacizumab slows progression but has no overall survival benefit

The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

Yale experts uncover genes associated with immune response to flu vaccination

Yale experts and their partners in a national research consortium have identified several genes and gene clusters associated with the immune response to flu vaccination.

Significant gaps in public awareness about cardiovascular risks from tobacco use, secondhand smoke

A report released today at the World Heart Federation World Congress of Cardiology in Dubai reveals significant gaps in public awareness regarding the cardiovascular risks of tobacco use and secondhand smoke. The report, entitled "Cardiovascular harms from tobacco use and secondhand smoke", was commissioned by the World Heart Federation and written by the International Tobacco Control Project (ITC Project), in collaboration with the Tobacco Free Initiative at the World Health Organization.

BioFocus to use DiscoveRx's GPCR screening assay and associated cell lines

DiscoveRx Corp. and BioFocus® announced today that they have signed a co-marketing agreement that allows BioFocus to perform screening on behalf of BioFocus' customers using DiscoveRx PathHunter™ ß-Arrestin GPCR screening assay, HitHunter™ cAMP assays and associated cell lines.

Dr Laurie Harris, DO - General Practice in Crandall, TX